Post-market surveillance has become a central focus of pharmacovigilance in the UK as regulatory expectations continue to evolve in 2026. Following the UK’s independent regulatory framework, there is a stronger emphasis on proactive safety monitoring throughout a medicinal product’s lifecycle. The Medicines and Healthcare products Regulatory Agency now expects Marketing Authorisation Holders to demonstrate continuous oversight of product safety rather than relying solely on periodic reporting.
In 2026, post-market surveillance in the UK is increasingly data-driven and risk-based. Companies are expected to strengthen their safety frameworks and demonstrate active control over post-authorisation safety activities.
Key regulatory priorities now include:
- Continuous monitoring of product safety throughout the lifecycle
- Faster detection and management of emerging safety signals
- Greater accountability of Marketing Authorisation Holders
- Clear documentation and traceability of safety decisions
- Improved protection of patient safety in real-world use
Why Post-Market Surveillance Needed Stronger Regulation in the UK
Traditional post-market surveillance systems were largely dependent on spontaneous adverse event reporting and scheduled safety reviews. While these approaches provided valuable insights, they often resulted in delayed signal detection and limited visibility of real-world safety issues.
With wider patient access to medicines, advanced therapies, and digital healthcare systems, UK regulators have strengthened PV expectations. The objective is earlier identification of safety concerns, better use of available data, and more effective risk management across the product lifecycle.
Key Changes in UK PV Regulations for 2026
1. Continuous Safety Monitoring
UK PV regulations now require ongoing benefit-risk evaluation throughout the product lifecycle. Safety data must be reviewed continuously rather than only during defined reporting periods. This approach supports earlier identification of emerging risks and faster regulatory action when required.
Regulatory expectations include:
- Ongoing review of adverse event data
- Continuous benefit-risk assessment
- Timely internal escalation of safety concerns
2. Expanded Use of Real-World Data
The use of real-world data has become a core component of post-market surveillance in the UK. Regulators expect companies to incorporate data from healthcare records, patient registries, and other real-world sources to support safety evaluations.
This approach provides a clearer understanding of how medicines perform in routine clinical practice across diverse patient populations.
Key benefits include:
- Improved detection of rare and long-term safety issues
- Enhanced safety evaluation in real-world settings
- Stronger post-authorisation safety evidence
3. Stronger Signal Detection and Risk Management
Signal detection requirements have become more robust in 2026. UK regulators expect earlier signal identification, thorough scientific assessment, and clear documentation of decision-making processes. Risk Management Plans must be regularly updated to reflect new safety information.
Static or outdated risk documents are no longer acceptable.
Focus areas include:
- Timely signal validation and assessment
- Regular review of risk minimisation measures
- Ongoing updates to Risk Management Plans
4. Tighter Reporting Timelines and Transparency
UK PV regulations place greater emphasis on timely and transparent reporting. Marketing Authorisation Holders must ensure that post-market safety findings are reported within required timelines and supported by clear justification.
Incomplete documentation or delayed reporting may lead to regulatory findings during inspections.
Key expectations include:
- Prompt submission of safety reports
- Clear rationale for safety-related decisions
- Robust audit trails and data traceability
5. Increased Accountability and Inspection Focus
Post-market surveillance systems are now a key focus during UK regulatory inspections. Inspectors assess not only compliance with procedures but also the effectiveness of PV systems in protecting patient safety.
Organisations must demonstrate that their pharmacovigilance activities are actively identifying and managing risks.
Inspection focus areas include:
- Effectiveness of signal management processes
- Quality and consistency of safety data
- Training and competency of PV staff
Impact on UK Pharmaceutical Companies
These regulatory changes require UK-based pharmaceutical companies to strengthen their PV systems, invest in skilled personnel, and adopt more proactive safety strategies. Organisations that adapt early are better positioned to manage regulatory expectations and maintain public trust.
A robust post-market surveillance framework also supports smoother inspections and more effective regulatory interactions.
How Q&V Can Support UK-Based Organisations
Q & V works closely with UK pharmaceutical companies to support compliance with evolving post-market surveillance and pharmacovigilance requirements.
Our services include:
- UK PV system and post-market surveillance gap assessments
- Support with MHRA-aligned PV compliance strategies
- Signal management and risk management optimisation
- PSUR, PBRER, and post-authorisation safety support
- Inspection readiness and audit preparation
- PV training for UK-based safety teams
Q&V combines regulatory expertise with practical implementation support to help organisations meet UK PV expectations in 2026.
Speak to Q&V today and ensure your PV framework remains compliant, effective, and inspection-ready.